Ocrelizumab/hyaluronidase


Ocrelizumab/hyaluronidase, sold under the brand name Ocrevus Zunovo, is a fixed-dose combination medication used for the treatment of multiple sclerosis. It contains ocrelizumab, a recombinant humanized monoclonal antibody directed at CD20; and hyaluronidase, an endoglycosidase. It is taken by subcutaneous injection.
Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.

Medical uses

Ocrelizumab/hyaluronidase is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease; and primary progressive multiple sclerosis.